Johnson & Johnson's nipocalimab has received Fast Track designation from the FDA for treating Sjögren's disease, a chronic autoimmune condition with no approved advanced therapies. The drug is also being evaluated for other autoimmune diseases, showing promising results in clinical trials.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing